
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corp is witnessing strong growth, particularly in its Corneal Health segment, which is expected to grow by 9.4% for FY26, with significant momentum anticipated in the latter half as improved reimbursement for Epioxa is expected. The company has seen favorable sales performance for its iDose product, with revenue estimates for FY26 being adjusted upward to $205 million due to increased expectations surrounding repeat administration of the therapy, alongside an impressive gross margin of 85.1% that exceeded consensus forecasts. Additionally, Corneal Health revenue reached $24 million, surpassing consensus estimates of $18 million and demonstrating a year-over-year growth rate of 12%, indicating strong commercial traction and demand for Glaukos's innovative products.
Bears say
Glaukos Corp's recent financial performance, while showing some positive revenue growth in both domestic and international markets for glaucoma treatments, reveals a concerning trend with decreasing growth rates and emerging challenges in market dynamics. The company has revised its sales growth expectations downward for its minimally invasive glaucoma surgery (MIGS) products, reflecting anticipated headwinds in both domestic and international markets. Furthermore, the downward adjustment of 2026 and 2027 adjusted earnings per share (EPS) projections indicates a deteriorating financial outlook that may be exacerbated by competition, changes in reimbursement policies, and slower product adoption rates.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares